• 1
    Olayioye MA, Neve RM, Lane HS, Hynes NE. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 2000; 19: 31593167.
  • 2
    Hung MC, Lau YK. Basic science of HER-2/neu: a review. Semin Oncol. 1999; 26( suppl 12): 5159.
  • 3
    Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989; 244: 707712.
  • 4
    Buchholz TA, Tu X, Ang KK, et al. Epidermal growth factor receptor expression correlates with poor survival in patients who have breast carcinoma treated with doxorubicin-based neoadjuvant chemotherapy. Cancer. 2005; 104: 676681.
  • 5
    Skasko E, Paszko Z, Masur S. A new look at the prognostic value of the estrogen, progesterone and epidermal growth factor receptors in breast cancer tissue. Neoplasma. 2005; 52: 1017.
  • 6
    Tsutsui S, Ohno S, Murakami S, Hachitanda Y, Oda S. Prognostic value of epidermal growth factor receptor status in 1029 patients with breast cancer. Breast Cancer Res Treat. 2002; 71: 6775.
  • 7
    Carney WP, Neumann R, Lipton A, Leitzel K, Ali S, Price CP. Potential utility of serum HER-2/neu oncoprotein concentrations in patients with breast cancer. Clin Chem. 2003; 49: 15791598.
  • 8
    Ali SA, Leitzel K, Chinchilli VM, et al. Relationship of serum HER-2/neu and serum CA 15-3 in patients with metastatic breast cancer. Clin Chem. 2002; 48: 13141320.
  • 9
    Bewick M, Chadderton T, Conlon M, et al. Expression of c-erbB-2/HER-2 in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous blood stem cell support. Bone Marrow Transplant. 1999; 24: 377384.
  • 10
    Fehm T, Jager W, Kramer S, et al. Prognostic significance of serum HER2 and CA15-3 at the time of diagnosis of metastatic breast cancer. Anticancer Res. 2004; 24: 19871992.
  • 11
    Harris LN, Liotcheva V, Broadwater G, et al. Comparison of methods of measuring HER-2 in metastatic breast cancer patients treated with high-dose chemotherapy. J Clin Oncol. 2001; 19: 16981706.
  • 12
    Hayes DF, Yamauchi H, Broadwater G, et al. Cancer and Leukemia Group B: circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer. Cancer and Leukaemia group B study 8662. Clin Cancer Res. 2001; 7: 27032711.
  • 13
    Colomer R, Llombard-Cussac A, Lluch A, et al. Biweekly paclitaxel plus gemcitabine in advanced breast cancer: phase II trial and predictive value of HER-2 extracellular domain. Ann Oncol. 2004; 15: 201206.
  • 14
    Muller V, Witzel I, Luck HJ, et al. Prognostic and predictive impact of the HER-2/neu extracellular domain (ECD) in the serum of patients treated with chemotherapy for metastatic breast cancer. Breast Cancer Res Treat. 2004; 86: 918.
  • 15
    Lipton A, Ali SM, Leitzel K, et al. Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. J Clin Oncol. 2002, 20: 14671472.
  • 16
    Esteva FJ, Valero V, Booser D, et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol. 2002; 20: 18001808.
  • 17
    Burstein HJ, Harris LN, Marcom PK, et al. Trastuzumab and vinorelbine as first-line therapy for HER-2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol. 2003; 21: 28892895.
  • 18
    Kostler WJ, Schwab B, Singer CF, et al. Monitoring serum Her-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer. Clin Cancer Res. 2004; 10: 16181624.
  • 19
    Esteva FJ, Cheli CD, Fritsche H, et al. Clinical utility of serum HER-2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies. Breast Cancer Res. 2005; 7: R436443.
  • 20
    Gasparini G, Sarmiento R, Amici S, et al. Gefitinib (ZD1839) combined with weekly epirubicin in patients with metastatic breast cancer: a phase I study with biological correlate. Ann Oncol. 2005; 16: 18671873.
  • 21
    Lafky MJ, Baron AT, Cora EM, et al. Serum soluble epidermal growth factor receptor concentrations decrease in postmenopausal metastatic breast cancer patients treated with letrozole. Cancer Res. 2005; 65: 30593062.
  • 22
    Hudelist G, Kostler WJ, Gschwantler-Kaulich D, et al. Serum EGFR levels and efficacy of trastuzumab based therapy in patients with metastatic breast cancer. Eur J Cancer. 2006; 42: 186192.
  • 23
    Muller V, Witzel I, Pantel K, et al. Prognostic and predictive impact of soluble epidermal growth factor receptor (sEGFR) in the serum of patients treated with chemotherapy for metastatic breast cancer. Anticancer Res. 2006; 26: 14791488.
  • 24
    Colleoni M, Rocca A, Sandri MT, et al. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor. Ann Oncol. 2002; 13: 7380.
  • 25
    Colleoni M, Orlando L, Sanna G, et al. Metronomic low dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects. Ann Oncol. 2006; 17: 232238.
  • 26
    Sandri MT, Johansson H, Colleoni M, et al. Serum levels of HER-2 ECD can determine the response rate to low dose oral cyclophosphamide and methotrexate in patients with advanced stage breast carcinoma. Anticancer Res. 2004; 24: 12611266.
  • 27
    Payne RC, Allard JW, Anderson-Mauser L, Humphreys JD, Tenney DY, Morris DL. Automated assay for HER-2/neu in serum. Clin Chem. 2000; 46: 175182.
  • 28
    Cook GB, Neaman IE, Goldblatt JL, et al. Clinical utility of serum HER-2/neu testing on the Bayer Immuno1 automated system in breast cancer. Anticancer Res. 2001; 21: 14651470.
  • 29
    Schwartz MK, Smith C, Schwartz DC, Dnistrian A, Neiman I. Monitoring therapy by serum HER-2/neu. Int J Biol Marker. 2000; 15: 324329.
  • 30
    Cold S, Jensen NV, Brincker H, Rose C. The influence of chemotherapy on survival after recurrence in breast cancer—a population-based study of patients treated in the 1950s, 1960s and 1970s. Eur J Cancer. 1993; 29A: 11461152.
  • 31
    Kerbel RS. Antiangiogenic therapy: a universal chemo sensitization strategy for cancer? Science. 2006; 312: 11711175.
  • 32
    Munoz R, Man S, Shaked Y, et al. Highly efficacious non-toxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy. Cancer Res. 2006; 66: 33863391.
  • 33
    Glode LM, Barqawi A, Crighton F, Crawford ED, Kerbel R. Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma. Cancer. 2003; 98: 16431648.
  • 34
    Vogt T, Hafner C, Bross K, et al. Anti-angiogenetic therapy with pioglitazone, rofecoxib, and metronomic trofosfamide in patients with advanced malignant vascular tumors. Cancer. 2003; 98: 22512256.
  • 35
    Spieth K, Kaufmann R, Gille J. Metronomic oral low-dose treosulfan chemotherapy combined with cyclooxygenase-2 inhibitor in pre-treated advanced melanoma: a pilot study. Cancer Chemother Pharmacol. 2003; 52: 377382.
  • 36
    Bottini A, Generali D, Brizzi MP, et al. Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients. J Clin Oncol. 2006; 24: 36233628.
  • 37
    Dnistrian AM, Schwartz MK, Schwartz DC, Ghani F, Kish L. Significance of serum her-2/neu oncoprotein, CA 15-3 and CEA in the clinical evaluation of metastatic breast cancer. JClin Ligand Assay. 2002; 25: 215220.
  • 38
    Fornier MN, Seidman AD, Schwartz MK, et al. Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER-2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate. Ann Oncol. 2005; 16: 234239.
  • 39
    Im SA, Kim SB, Lee MH, et al. Docetaxel plus epirubicin as first-line chemotherapy in MBC (KCSG 01-10-05): phase II trial and the predictive values of circulating HER2 extracellular domain and vascular endothelial growth factor. Oncol Rep. 2005; 14: 481487.
  • 40
    Luftner D, Henschke P, Flath B, et al. Serum Her-2/neu as a prediction and monitoring parameter in a phase II study with weekly paclitaxel in metastatic breast cancer. Anticancer Res. 2004; 14: 895906.
  • 41
    Schippinger W, Regitnig P, Bauernhofer T, et al. The course of serum HER-2/neu levels as an independent prognostic factor for survival in metastatic breast cancer. Oncol Rep. 2004; 11: 13311336.
  • 42
    Yang W, Klos K, Yang Y, Smith TL, Shi D, Yu D. ErbB2 overexpression correlates with increased expression of vascular endothelial growth factors A, C and D in human breast carcinoma. Cancer. 2002; 94: 28552861.
  • 43
    Yen L, Benlimame M, Nie ZR, et al. Differential regulation of tumor angiogenesis by distinct ErbB homo- and heterodimers. Mol Biol Cell. 2002; 13: 49294944.
  • 44
    Mancuso P, Colleoni M, Calleri A, et al. Circulating endothelial-cell kinetics and viability predicts survival in breast cancer patients receiving metronomic chemotherapy. Blood. 2006; 15: 452459.
  • 45
    Ali SM, Esteva FJ, Fornier M, et al. Serum Her-2/neu change predicts clinical outcome to trastuzumab-based therapy [abstract]. Proc ASCO. 2006; 3s. Abstract 500.
  • 46
    Souder C, Leitzel K, Ali SM, et al. Serum epidermal growth factor receptor/HER-2 predicts poor survival in patients with metastatic breast cancer. Cancer. 2006; 107: 23372345.
  • 47
    Goldman CK, Kim J, Wong WL, King V, Brock T, Gillespie GY. Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology. Mol Biol Cell. 1993; 4: 121133.
  • 48
    Graus-Porta D, Beerli RR, Hynes NE. Single-chain antibody-mediated intracellular retention of ErbB-2 impairs Neu differentiation factor and epidermal growth factor signalling. Mol Cell Biol. 1995; 15: 11821191.
  • 49
    Graus-Porta D, Beerli RR, Daly JM, Hynes NE. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signalling. EMBO J. 1997; 16: 16471655.
  • 50
    Cristofanilli M, Budd T, Ellis M et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004; 351: 781791.